Fixing dialysis care
Fixing dialysis care
GraftWorx has developed a noninvasive remote monitoring solution for fluid management in hemodialysis patients. Our solution will generate $8 billion of value by growing revenue for dialysis providers and creating cost savings for payers. The GraftWorx system has been validated on 115 patients across 3 clinical studies and we expect to receive FDA clearance in late 2019. We have closed a strategic partnership with WL Gore and a clinical partnership with a prospective dialysis customer who manages ~6,000 patients.
Founders
View all team membersFounder, GraftWorx. Founded O2 Insights (Sold to Systagenix). Also a PhD in Biomedical Engineering
Founder and CEO of @GraftWorx • Attended medical school and Research at @National Institutes of Health • Studied at @Grove City College
Funding
View all fundingTotal raised
$2.9M
Funded over
1 round
Latest round
Seed (Jun 2016)
Jobs
GraftWorx hasn't added any jobs yet
Get notified when GraftWorx posts new jobs.